In this podcast, Luis Paz-Ares explains the updated results of the CASPIAN trial which assessed durvalumab, with or without tremelimumab, in combination with etoposide plus either cisplatin or carboplatin (platinum-etoposide) in treatment-naive patients with extensive-stage small-cell lung cancer. Listen now to hear more about the results and implications of this study.
